You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海凱寶(300039.SZ)及子公司共有93個藥品納入國家醫保目錄(2021年)
格隆匯 12-03 19:43

格隆匯12月3日丨上海凱寶(300039.SZ)公佈,2021年12月3日,國家醫保局、人力資源社會保障部發布了《關於印發<國家基本醫療保險、工傷保險和生育保險藥品目錄(2021年)>的通知》(醫保發〔2021〕50號),公佈了《國家基本醫療保險、工傷保險和生育保險藥品目錄》。

據統計,公司及子公司共有93個藥品納入國家醫保目錄,其中甲類50個,乙類43個。主要產品:獨家品種3個(公司產品痰熱清注射液、痰熱清膠囊,子公司產品芪參膠囊),獨家劑型1個(公司產品多索茶鹼膠囊)等繼續進入《國家醫保目錄》。

公司產品痰熱清膠囊通過談判續約,繼續被納入《國家醫保目錄》之“協議期內談判藥品部分”,醫保支付標準為4.09元/(0.4g/粒),協議有效期為2022年1月1日至2023年12月31日,有效期滿後按照醫保相關規定再行調整。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account